Treatment of HIV infection with raltegravir.
BACKGROUND
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus.


OBJECTIVE
To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability.


METHODS
Data from pharmacokinetic, Phase II and III clinical trials were reviewed.


CONCLUSIONS
Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naïve and -experienced patients.
Chirch
Lisa M
LM
Division of Infectious Diseases, Stony Brook University School of Medicine, Health Sciences Center T15-080, Stony Brook, NY 11794-8153, USA. lisa.chirch@stonybrook.edu
Morrison
Sidonie
S
Steigbigel
Roy T
RT
D002986:Clinical Trials as Topic; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D011760:Pyrrolidinones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068898:Raltegravir Potassium
D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium